TIGIT and breast cancer: TIGIT was reported to be the key checkpoint receptor associated with NK cell dysfunction and exhaustion in several tumor-bearing mouse models (including colon cancer, melanoma, breast cancer, and fibrosarcoma) and in patients with CRC.